Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms
{{output}}
Decitabine is widely used in the treatment of chronic myeloid neoplasms, potentially through its immunomodulatory effects on CD8+ T cells and natural killer (NK) cells. However, as decitabine is often administered in combination with other agents and at varyin... ...
